과제정보
This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT, Korea (NRF-2022R1F1A1071409).
참고문헌
- Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6
- American College of Radiology. LI-RADS® CT/MRI. acr.org Web site. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/LI-RADS-CT-MRI-v2018. Accessed February 27, 2021
- Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology 2018;68:723-750 https://doi.org/10.1002/hep.29913
- European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236 https://doi.org/10.1016/j.jhep.2018.03.019
- Kim DH, Choi SH, Park SH, Kim KW, Byun JH, Kim SY, et al. Liver imaging reporting and data system category M: a systematic review and meta-analysis. Liver Int 2020;40:1477-1487 https://doi.org/10.1111/liv.14420
- Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-380 https://doi.org/10.1002/hep.29086
- Kim SS, Lee S, Choi JY, Lim JS, Park MS, Kim MJ. Diagnostic performance of the LR-M criteria and spectrum of LI-RADS imaging features among primary hepatic carcinomas. Abdom Radiol (NY) 2020;45:3743-3754 https://doi.org/10.1007/s00261-020-02562-y
- Sammon J, Fischer S, Menezes R, Hosseini-Nik H, Lewis S, Taouli B, et al. MRI features of combined hepatocellular-cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma. Cancer Imaging 2018;18:8
- Park HJ, Kim YK, Cha DI, Ko SE, Kim S, Lee ES, et al. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category. Clin Radiol 2020;75:478.e13-478.e23 https://doi.org/10.1016/j.crad.2020.01.002
- Choi SH, Lee SS, Park SH, Kim KM, Yu E, Park Y, et al. LI-RADS classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI. Radiology 2019;290:388-397 https://doi.org/10.1148/radiol.2018181290
- An C, Kim DW, Park YN, Chung YE, Rhee H, Kim MJ. Single hepatocellular carcinoma: preoperative MR imaging to predict early recurrence after curative resection. Radiology 2015;276:433-443 https://doi.org/10.1148/radiol.15142394
- An C, Park S, Chung YE, Kim DY, Kim SS, Kim MJ, et al. Curative resection of single primary hepatic malignancy: liver imaging reporting and data system category LR-M portends a worse prognosis. AJR Am J Roentgenol 2017;209:576-583 https://doi.org/10.2214/AJR.16.17478
- Jeon SK, Joo I, Lee DH, Lee SM, Kang HJ, Lee KB, et al. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 2019;29:373-382 https://doi.org/10.1007/s00330-018-5605-x
- Shin J, Lee S, Kim SS, Chung YE, Choi JY, Park MS, et al. Characteristics and early recurrence of hepatocellular carcinomas categorized as LR-M: comparison with those categorized as LR-4 or 5. J Magn Reson Imaging 2021;54:1446-1454 https://doi.org/10.1002/jmri.27650
- Ariizumi S, Kitagawa K, Kotera Y, Takahashi Y, Katagiri S, Kuwatsuru R, et al. A non-smooth tumor margin in the hepatobiliary phase of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging predicts microscopic portal vein invasion, intrahepatic metastasis, and early recurrence after hepatectomy in patients with hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2011;18:575-585 https://doi.org/10.1007/s00534-010-0369-y
- Cho ES, Choi JY. MRI features of hepatocellular carcinoma related to biologic behavior. Korean J Radiol 2015;16:449-464 https://doi.org/10.3348/kjr.2015.16.3.449
- Sakon M, Nagano H, Nakamori S, Dono K, Umeshita K, Murakami T, et al. Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy: analysis based on tumor hemodynamics. Arch Surg 2002;137:94-99 https://doi.org/10.1001/archsurg.137.1.94
- Kim KA, Kim MJ, Jeon HM, Kim KS, Choi JS, Ahn SH, et al. Prediction of microvascular invasion of hepatocellular carcinoma: usefulness of peritumoral hypointensity seen on gadoxetate disodium-enhanced hepatobiliary phase images. J Magn Reson Imaging 2012;35:629-634 https://doi.org/10.1002/jmri.22876
- Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Sone Y, et al. Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. J Hepatol 2013;58:1174-1180 https://doi.org/10.1016/j.jhep.2013.01.030
- Kim DK, An C, Chung YE, Choi JY, Lim JS, Park MS, et al. Hepatobiliary versus extracellular MRI contrast agents in hepatocellular carcinoma detection: hepatobiliary phase features in relation to disease-free survival. Radiology 2019;293:594-604 https://doi.org/10.1148/radiol.2019190414
- Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Geneva: World Health Organization, 2010
- Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:149-157 https://doi.org/10.1007/s00261-017-1196-2
- Min JH, Kim JM, Kim YK, Kim H, Choi GS, Kang TW, et al. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions. Eur Radiol 2022;32:912-922 https://doi.org/10.1007/s00330-021-08124-0
- Cannella R, Fraum TJ, Ludwig DR, Borhani AA, Tsung A, Furlan A, et al. Targetoid appearance on T2-weighted imaging and signs of tumor vascular involvement: diagnostic value for differentiating HCC from other primary liver carcinomas. Eur Radiol 2021;31:6868-6878 https://doi.org/10.1007/s00330-021-07743-x
- Motosugi U, Murakami T, Lee JM, Fowler KJ, Heiken JP, Sirlin CB; LI-RADS HBA Working Group. Recommendation for terminology: nodules without arterial phase hyperenhancement and with hepatobiliary phase hypointensity in chronic liver disease. J Magn Reson Imaging 2018;48:1169-1171 https://doi.org/10.1002/jmri.26515
- Bae JS, Lee JM, Yoon JH, Jang S, Chung JW, Lee KB, et al. How to best detect portal vein tumor thrombosis in patients with hepatocellular carcinoma meeting the Milan criteria: gadoxetic acid-enhanced MRI versus contrast-enhanced CT. Liver Cancer 2020;9:293-307 https://doi.org/10.1159/000505191
- Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007;99:998-1003 https://doi.org/10.1093/jnci/djm024
- Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711 https://doi.org/10.1093/jnci/djn134
- Liu Y, Yang T, Wei YW. What is the difference between overall survival, recurrence-free survival and time-to-recurrence? Br J Surg 2020;107:e634
- Yang H, Bae SH, Nam H, Lee HL, Lee SW, Yoo SH, et al. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol 2022;77:632-641 https://doi.org/10.1016/j.jhep.2022.03.032
- Park SY, Park JE, Kim H, Park SH. Review of statistical methods for evaluating the performance of survival or other time-to-event prediction models (from conventional to deep learning approaches). Korean J Radiol 2021;22:1697-1707 https://doi.org/10.3348/kjr.2021.0223
- Rhee H, An C, Kim HY, Yoo JE, Park YN, Kim MJ. Hepatocellular carcinoma with irregular rim-like arterial phase hyperenhancement: more aggressive pathologic features. Liver Cancer 2019;8:24-40 https://doi.org/10.1159/000488540
- Park SH, Lee SS, Yu E, Kang HJ, Park Y, Kim SY, et al. Combined hepatocellular-cholangiocarcinoma: gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging 2017;46:267-280 https://doi.org/10.1002/jmri.25568
- Rhee H, Cho ES, Nahm JH, Jang M, Chung YE, Baek SE, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol 2021;74:109-121 https://doi.org/10.1016/j.jhep.2020.08.013
- Kim B, Won JH, Kim J, Kwon Y, Cho HJ, Huh J, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: radiologic and clinical factors predictive of survival. AJR Am J Roentgenol 2021;216:1566-1573 https://doi.org/10.2214/AJR.20.23213
- Min JH, Kim YK, Choi SY, Kang TW, Lee SJ, Kim JM, et al. Intrahepatic mass-forming cholangiocarcinoma: arterial enhancement patterns at MRI and prognosis. Radiology 2019;290:691-699 https://doi.org/10.1148/radiol.2018181485
- Joo I, Kim SY, Kang TW, Kim YK, Park BJ, Lee YJ, et al. Radiologic-pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid-enhanced MRI: a multicenter study. Radiology 2020;296:335-345 https://doi.org/10.1148/radiol.2020192275
- Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, et al. Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology 2013;266:480-490 https://doi.org/10.1148/radiol.12112677
- Kang Y, Lee JM, Kim SH, Han JK, Choi BI. Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 2012;264:751-760 https://doi.org/10.1148/radiol.12112308
- Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol 2013;20:325-339 https://doi.org/10.1245/s10434-012-2513-1
- Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep 2017;7:12870